<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527421</url>
  </required_header>
  <id_info>
    <org_study_id>DFD01-CD-013</org_study_id>
    <nct_id>NCT02527421</nct_id>
  </id_info>
  <brief_title>DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encore Dermatology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prosoft Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Encore Dermatology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the&#xD;
      hypothalamic-pituitary-adrenal (HPA) axis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the&#xD;
      hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days or when&#xD;
      applied twice daily for 29 days, in adolescent subjects with moderate to severe plaque&#xD;
      psoriasis under maximal use conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not able to recruit patients with the current enrollment criteria.&#xD;
  </why_stopped>
  <start_date type="Actual">August 19, 2015</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With HPA Axis Suppression at End of Treatment (Day 15 or Day 28) With Recovery 29 Days Later</measure>
    <time_frame>End of Treatment (day 15 or day 28) with recovery 29 days later</time_frame>
    <description>Number of participants with HPA axis suppression at End of Treatment (day 15 or day 28) with recovery 29 days later, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With HPA Axis Suppression at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Number of participants with HPA axis suppression at Day 29, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DFD01 Spray Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD01 spray, twice daily, 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFD01 Spray Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD01 spray, twice daily, 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD01 Spray</intervention_name>
    <description>DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
    <arm_group_label>DFD01 Spray Group 1</arm_group_label>
    <arm_group_label>DFD01 Spray Group 2</arm_group_label>
    <other_name>betamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must weigh at least 55 pounds&#xD;
&#xD;
          2. Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque&#xD;
             psoriasis.&#xD;
&#xD;
          3. Subjects with psoriasis involving â‰¥ 10% BSA, not including the face, scalp, groin,&#xD;
             axillae and other intertriginous areas..&#xD;
&#xD;
          4. Subjects must have moderate to severe plaque psoriasis at the Baseline Visit.&#xD;
&#xD;
          5. Subjects whose results from the screening ACTH stimulation test are considered normal&#xD;
             (cortisol level &gt;18 ug/dL at 30 minutes post stimulation) and show no other signs of&#xD;
             abnormal HPA axis function or adrenal response.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,&#xD;
             exfoliative or pustular psoriasis.&#xD;
&#xD;
          2. History of organ transplant requiring immunosuppression, HIV, or other&#xD;
             immunocompromised state.&#xD;
&#xD;
          3. Have received treatment for any type of cancer within 5 years of the Baseline Visit.&#xD;
&#xD;
          4. Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g.,&#xD;
             tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate,&#xD;
             cyclosporine, hydroxyurea), or 3) biologic treatment for psoriasis (e.g., infliximab,&#xD;
             adalimumab, etanercept, ustekinumab, secukinumab, or alefacept).&#xD;
&#xD;
          5. Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs&#xD;
             (salicylic acid, anthralin, coal tar, calcipotriene), 2) PUVA therapy, 3) systemic&#xD;
             anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine),&#xD;
             or 4) UVB therapy.&#xD;
&#xD;
          6. Use within 30 days prior to the Screening Visit of any product containing&#xD;
             corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.&#xD;
&#xD;
          7. Subjects who have an abnormal sleep schedule or work overnight.&#xD;
&#xD;
          8. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased&#xD;
             adrenal output, low pituitary function or pituitary tumors.&#xD;
&#xD;
          9. Subjects who have a history of an adverse reaction to cosyntropin injection or similar&#xD;
             test reagents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Sidgiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-1385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 100</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02527421/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DFD01 Spray Group 1</title>
          <description>DFD01 spray, twice daily, 15 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
        <group group_id="P2">
          <title>DFD01 Spray Group 2</title>
          <description>DFD01 spray, twice daily, 29 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DFD01 Spray Group 1</title>
          <description>DFD01 spray, twice daily, 15 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
        <group group_id="B2">
          <title>DFD01 Spray Group 2</title>
          <description>DFD01 spray, twice daily, 29 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With HPA Axis Suppression at End of Treatment (Day 15 or Day 28) With Recovery 29 Days Later</title>
        <description>Number of participants with HPA axis suppression at End of Treatment (day 15 or day 28) with recovery 29 days later, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
        <time_frame>End of Treatment (day 15 or day 28) with recovery 29 days later</time_frame>
        <population>Subjects who completed the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>DFD01 Spray Group 1</title>
            <description>DFD01 spray, twice daily, 15 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
          </group>
          <group group_id="O2">
            <title>DFD01 Spray Group 2</title>
            <description>DFD01 spray, twice daily, 29 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With HPA Axis Suppression at End of Treatment (Day 15 or Day 28) With Recovery 29 Days Later</title>
          <description>Number of participants with HPA axis suppression at End of Treatment (day 15 or day 28) with recovery 29 days later, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
          <population>Subjects who completed the treatment period</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With HPA Axis Suppression at Day 29</title>
        <description>Number of participants with HPA axis suppression at Day 29, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DFD01 Spray Group 1</title>
            <description>DFD01 spray, twice daily, 15 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
          </group>
          <group group_id="O2">
            <title>DFD01 Spray Group 2</title>
            <description>DFD01 spray, twice daily, 29 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With HPA Axis Suppression at Day 29</title>
          <description>Number of participants with HPA axis suppression at Day 29, by measuring the level of cortisol in the blood after ACTH stimulation test</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>43 days (14-day treatment group) or 57 days (29-day treatment group)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DFD01 Spray Group 1</title>
          <description>DFD01 spray, twice daily, 15 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
        <group group_id="E2">
          <title>DFD01 Spray Group 2</title>
          <description>DFD01 spray, twice daily, 29 days&#xD;
DFD01 Spray: DFD-01 (betamethasone dipropionate) Spray, 0.05%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HPA Axis suppression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No report, abstract, oral presentation, or publication of the results of the Study proposed by Institution shall be presented or published without the prior written consent of the Sponsor or as otherwise permitted for regulatory agency inspections.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Babilon President</name_or_title>
      <organization>Prosoft Clinical</organization>
      <phone>484 320 2068</phone>
      <email>b.babilon@prosoftclinical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

